Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

Pharming

16 February 2023 - EMA marketing authorisation application for leniolisib changed to standard review timetable.

Pharming announces that the  EMA's CHMP has decided to shift its assessment of the marketing authorisation application for leniolisib to a standard review timetable.

Read Pharming press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Europe , Timelines , Dossier